Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 96Triple Negative Breast Neoplasms 42Breast Neoplasms, Male 18Inflammatory Breast Neoplasms 11Neoplasm Metastasis 8Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Stomach Neoplasms 4Prostatic Neoplasms 4Pancreatic Neoplasms 4Esophageal Neoplasms 4Endometrial Neoplasms 4Anatomic Stage I Breast Cancer AJCC v8 4Sarcoma 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Testicular Neoplasms 2Small Cell Lung Carcinoma 2Salivary Gland Neoplasms 2Neoplasms, Unknown Primary 2Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Breast Carcinoma In Situ 2Anatomic Stage II Breast Cancer AJCC v8 2Uterine Cervical Neoplasms 1Thrombocytosis 1

Interventions

pembrolizumab 1eribulin 1Taxes 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Inoperable Locally Advanced HER2-Negative Breast Cancer × Taxes × Breast × Clear all
NCT06942234 2025-09-17

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 1/2 Recruiting
180 enrolled
Breast

Inoperable Locally Advanced HER2-Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡